NEW YORK, July 1, 2026, 13:06 (EDT)
- Hims & Hers Health NYSE:HIMS shares climbed 9.5% to $37.97 after Canaccord Genuity bumped its price target up to $40 from $32. The new level puts just under 5% room left, according to analysts.
- Hims lists its lowest GLP-1 pill price at $149 a month, though its weight-loss membership starts at $39 for the first month and then goes to $149 a month after that, on top of the drug price.
- Medicare is launching the GLP-1 Bridge with a $50 monthly copay for eligible Part D patients, introducing a fresh price point as investors track out-of-pocket demand for weight-loss drugs.
Hims & Hers Health NYSE:HIMS jumped 9.5% to $37.97 by midday after Canaccord Genuity’s Maria Ripps raised her target price to $40 from $32 and left her Buy call unchanged. The new target is about 5% above the current level, after a 25% bump in the target price.
The investor story isn’t about bulk drug sales now, but regular cash subscriptions. Hims offers Wegovy at $149 per month, but buyers have to sign up for a Hims Weight Loss membership too—$39 for month one, then $149 monthly. Hims says this is a separate charge, and membership doesn’t mean you’ll get a prescription.
| Access route | Patient price signal | Investor read-through |
|---|---|---|
| Hims self-pay, lowest listed GLP-1 pill | $188 for the first month, then $298 monthly if prescribed | Subscription model boosts revenue per user, but the price gap gets bigger |
| Medicare GLP-1 Bridge | $50 a month copay for Part D patients who qualify | Medicare may pull older users away from direct-pay telehealth |
| Manufacturer cash-pay pills | About $149 monthly for the Novo Nordisk NYSE:NVO Wegovy pill or Eli Lilly NYSE:LLY Foundayo pill | Drugmakers are putting out a low direct-pay base price |
| Employer coverage | 5% to 10% of employers with coverage now plan to exit GLP-1 weight loss coverage in 2027 | Workers losing plans may move to telehealth options |
Employer coverage isn’t as strong, but it’s still holding up. Mercer told Reuters that 5% of big companies who now cover GLP-1 obesity drugs say they expect to drop coverage by 2027. Business Group on Health put the current rate at 10% for employers that now offer it. Cigna Group NYSE:CI is cutting coverage for its own staff starting in July, according to Reuters.
Lauren Remspecher, director at Purchaser Business Group on Health, said direct prices show employers “how much more they’re paying.” Louis Zollo, pharmacy practice leader at Segal, said “the patient population keeps growing.” Reuters
Hims is still seeing strong demand. Analysts polled by Reuters are looking for $2.89 billion in revenue for this year, rising to $3.45 billion by 2027. Raul Shah, CEO of DocShah Financial, said about a third of that now comes from weight loss—and expects that portion to “continue increasing.” Novo executive Jamey Millar called Hims one of the drugmaker’s most “voluminous” telehealth partners recently. Reuters
Hims said in March it would add Novo’s Ozempic shots and Wegovy pills and injections to its platform and stop marketing compounded GLP-1 products. CEO Andrew Dudum called the Novo deal a “new model that works for everyday people.” Hims said it couldn’t estimate how the deal might affect future results. Hims
| Investor check | Latest read | Why it matters |
|---|---|---|
| Share price | $37.97, up 9.5%; market value sits at $8.66 billion | Canaccord’s new $40 target is close to where shares trade |
| Canaccord target | $40, raised from $32 | Market sees about a 5% bump from here |
| Consensus sales cited by Reuters | $2.89 billion for 2026, $3.45 billion in 2027 | 2027 guidance would be 19% growth |
| Hims Q1 base | Revenue $608.1 million; subscribers at 2.584 million; gross margin 65%; net loss $92.1 million | Moving to branded drugs hits margins |
Hims posted first-quarter numbers showing where things tightened. Revenue was up 4% to $608.1 million, but U.S. sales dropped 8%. Gross margin narrowed, down at 65% from 73%. The company reported a net loss of $92.1 million after being in the black last year. Subscribers climbed 9% to 2.584 million, but monthly average revenue per subscriber slipped to $80 from $85.
Canaccord sees another sign for bulls. The firm said credit-card data showed sales growth picked up, moving from mid- to high-single digits in April to the high teens in June, per Investing.com. TipRanks puts the average Hims price target at $30.05, which is under the current price. The consensus is Moderate Buy.
Medicare’s new GLP-1 Bridge program is moving ahead. CMS rolled it out Wednesday with a $50 copay and a $245 net price per month outside the usual Part D setup. The program will run through Dec. 31, 2027. Reuters, citing KFF, said almost 4 million people might qualify. That’s well under the drug companies’ count, which goes as high as 20 million.
Dr. John Batsis at the University of North Carolina told Reuters the big worry for older people isn’t just losing weight. Juliette Cubanski, deputy director at KFF’s Medicare policy group, said the demo “doesn’t really represent a sustainable approach.” Reuters
The peptide side of the Hims story is still unresolved. FDA staff this week said there isn’t much evidence to let compounding pharmacies make seven major peptides. An advisory panel is set for July 23-24. Scott Brunner, who runs the Alliance for Pharmacy Compounding, called for the FDA to find a “middle path.” Reuters
Next up are second-quarter numbers. Hims expects Q2 revenue in a range of $680 million to $700 million and adjusted EBITDA between $35 million and $55 million. Its 2026 outlook calls for $2.8 billion to $3.0 billion in revenue and adjusted EBITDA of $275 million to $350 million.
